Scholarlink

<p><i>PDGFRB</i>-rearranged acute lymphoblastic leukemia (ALL), an <i>ABL</i>-class Ph-like ALL subtype, typically exhibits chemotherapy resistance and poor prognosis. Precise diagnosis and therapies are crucial for improving outcomes. Here, we report a case of a 9-year-old male harboring a <i>TERF2::PDGFRB</i> fusion, exhibiting primary resistance to dasatinib, but achieving a remarkable response to imatinib. Subsequent combination therapy with blinatumomab induced sustained bone marrow remission. These findings highlight the variability in tyrosine kinase inhibitors (TKIs) sensitivity among <i>PDGFRB</i>-rearranged ALL cases, supporting early treatment switching upon poor response. Notably, the combination of blinatumomab and imatinib may be an effective treatment strategy for <i>PDGFRB</i>-rearranged ALL.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Imatinib and blinatumomab successfully rescued a pediatric B-ALL patient with TERF2::PDGFRB fusion resistant to dasatinib and chemotherapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月20日

查看全文
  • Fanghua Ye,
  • Leyuan Wang,
  • Yujie Qian,
  • Wenjun Deng,
  • Yan Yu,
  • Liangchun Yang

摘要

PDGFRB-rearranged acute lymphoblastic leukemia (ALL), an ABL-class Ph-like ALL subtype, typically exhibits chemotherapy resistance and poor prognosis. Precise diagnosis and therapies are crucial for improving outcomes. Here, we report a case of a 9-year-old male harboring a TERF2::PDGFRB fusion, exhibiting primary resistance to dasatinib, but achieving a remarkable response to imatinib. Subsequent combination therapy with blinatumomab induced sustained bone marrow remission. These findings highlight the variability in tyrosine kinase inhibitors (TKIs) sensitivity among PDGFRB-rearranged ALL cases, supporting early treatment switching upon poor response. Notably, the combination of blinatumomab and imatinib may be an effective treatment strategy for PDGFRB-rearranged ALL.